NRIX · Nurix Therapeutics, Inc. · Executive Compensation
$14.00
-0.10 (-0.71%)
At close · Nov 19
Return incl. dividend (before tax)
Market Cap
$1.54B
Shares
109.25M
Volume · Nov 19
479.59K
Avg daily vol (3M)
2.43M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $6,374,138 |
| Gwenn M. Hansen | Chief Scientific Officer | $2,498,124 |
| Hans van Houte | Chief Financial Officer | $2,296,503 |
| Christine Ring | Chief Legal Officer and Chief Compliance Officer | $2,263,337 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $5,812,862 |
| Gwenn M. Hansen | Chief Scientific Officer | $2,033,860 |
| Christine Ring | Chief Legal Officer and Chief Compliance Officer | $2,016,484 |
| Hans van Houte | Chief Financial Officer | $2,016,482 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $4,363,120 |
| Gwenn M. Hansen | Chief Scientific Officer | $1,632,757 |
| Hans van Houte | Chief Financial Officer | $1,611,987 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $9,416,222 |
| Hans van Houte | Chief Financial Officer | $4,307,781 |
| Gwenn M. Hansen | Chief Scientific Officer | $3,824,583 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stefani A. Wolff | Chief Operating Officer and Executive Vice President, Product Development | $7,148,424 |
| Arthur T. Sands | M.D., Ph.D. President, Chief Executive Officer and Director | $4,791,466 |
| Gwenn M. Hansen | Chief Scientific Officer | $2,303,328 |
| Hans van Houte | Chief Financial Officer | $1,659,957 |
| Christine Ring | Ph.D., J.D. General Counsel and Secretary | $1,648,895 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | M.D., Ph.D. President, Chief Executive Officer and Director | $16,867,841 |
| Gwenn M. Hansen | Chief Scientific Officer | $1,552,577 |
| Christine Ring | Ph.D., J.D. General Counsel and Secretary | $1,307,091 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | M.D., Ph.D. President, Chief Executive Officer and Director | $1,481,610 |
| Gwenn M. Hansen | Chief Scientific Officer | $695,404 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Dansey, M.D. | director | Appointed | 2025-11-10 |
| Roy D. Baynes, MB.Bch., M.Med., Ph.D. | chair of the Clinical and Commercialization Committee | Appointed | 2025-08-22 |
|
Lori A. Kunkel, M.D.
“Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
chair of the Clinical and Commercialization Committee | Resigned | 2025-08-22 |
|
Lori A. Kunkel, M.D.
“Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
Class III director | Resigned | 2025-08-22 |
| Roy D. Baynes, MB.Bch., M.Med., Ph.D. | director | Appointed | 2025-03-13 |
| Anil Kapur | director | Appointed | 2024-10-16 |
| Stefani A. Wolff | Chief Operating Officer and Executive Vice President of Product Development | Resigned | 2023-04-10 |
| Edward C. Saltzman | director | Appointed | 2022-09-14 |
| Clay B. Siegall, Ph.D. | Class II member of the Board | Resigned | 2022-05-16 |
| Jeffrey K. Tong, Ph.D. | Class II member of the Board | Resigned | 2022-03-07 |
| Paul M. Silva | director | Appointed | 2021-09-30 |
| Judith A. Reinsdorf | director | Appointed | 2021-09-30 |
Leadership
- Arthur T. Sands CEO, Board Member
- Hans van Houte CFO
- Stefani Wolff COO
- Christine Ring General Counsel
- Anil Kapur Board Member
- Edward C. Saltzman Board Member
- Judith A. Reinsdorf Board Member
- Paul M. Silva Board Member
- Roger Dansey, M.D. Board Member
- Roy D. Baynes, MB.Bch., M.Med., Ph.D. Board Member
Key facts
CIK
1549595
CUSIP
67080M103
13F (30d)
245 filings
228 filers
Visit website
Investor relations